Depression and Anxiety in Patients with Bullous Pemphigoid: Impact and Management Challenges

This article was published in the following Dove Press journal:
Clinical, Cosmetic and Investigational Dermatology

Nicolas Kluger
Anna Pankakoski
Jaana Panelius
Department of Dermatology, Allergology and Venereology, Helsinki University Hospital, Helsinki, Finland

Abstract: Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. It is also associated with high mortality and poor prognosis due to advanced age of the patients and coexisting comorbidities. There is a dearth of data in the literature regarding depression and anxiety among those patients. The objective of this brief review is to discuss the intertwining relationship between depression and anxiety with bullous pemphigoid.

Keywords: anxiety, bullous pemphigoid, corticosteroids, depression, drug-induced bullous pemphigoid, quality of life

Introduction
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. It affects mainly the elderly patients aged \( \geq 65 \) years and displays its highest incidence after the age of 90. In Europe, its incidence ranges from 2.5 to 42.8 per 100,000 person-years. BP presents as tense blisters leaving erosions and crusts and erythema, associated with urticarial plaques and itch. BP is also associated with high mortality and poor prognosis due to advanced age of the patients and comorbidities. In this brief review, we discuss the relationships between depression and anxiety with BP (Figure 1).

Quality of Life in Patients with Bullous Pemphigoid
The morbidity of BP and its impact on the quality of life (QoL) are significant. BP causes significant physical discomfort (itchy patches, blisters, erosions) and physical limitations. Besides time spent on treatment, financial burden (high number of corticosteroid tubes, nurse at home) and social misconceptions should not be forgotten. For a patient treated with the recommended 30 g/day clobetasol propionate cream protocol, the costs for the treatment of one patient with potent topical corticosteroids during 4 months will be €174.80 (US$224.57) in the Netherlands. However, this pharmaco-economic evaluation does not include body application by home care nurses that can substantially increase the total costs. Studies have shown the impact on the QoL of patients with autoimmune bullous diseases (AIBD). However, most of these studies have focused on pemphigus or BP patients are analyzed along with other AIBD. To the best of our knowledge, only Kouris et al have specifically reported on BP’s impact on QoL. In their series of 57 patients with BP, they found that patients had higher scores for depression compared to sex- and gender-matched healthy controls, but did not find any difference for anxiety. The
Bullous pemphigoid and Neurological and Psychiatric Disorders

BP is associated with various comorbidities including neurological and psychiatric disorders. In Finland, Försti et al found patients with various central nervous system disorders were at higher risk of developing BP. They included multiple sclerosis, various forms of dementia, cerebral strokes, and hemorrhages as well as epilepsy. They also found various psychiatric conditions, mostly schizophrenia, and personality disorders, but also bipolar disorders and major depression as risk factors. Association with neurological conditions and psychiatric disorders have been observed also in other epidemiological studies. Link with psychiatric conditions is not consistently found in every series. Bastuji-Garin et al observed that patients with BP were more likely to have bipolar disorder (4%) compared with controls. Conversely, a large US study showed that patients with BP that were hospitalized were more likely to have psychoses or depression (among others) but no bipolar disorder. One appealing hypothesis is that neurodegeneration or neuroinflammation could lead to a cross-reactive immune response between neural and cutaneous antigens and the failure of self-tolerance. Indeed, BP autoantigens BP180 and BP230 are expressed in the central nervous system. Circulating BP antibodies have been found in some patients with neurological diseases such as dementia and Parkinson’s disease but is not known for patients with psychiatric conditions.

Drug-Induced Bullous Pemphigoid

Drug-induced BP is a well-known subset of BP. Medications to treat any associated comorbidities should be investigated. Until recently, the list of culprit drugs is rather small regarding psychiatric disorders. Neuroleptics have been reported to be associated, and anecdotal case reports have been published with risperidone or with fluoxetine. Varpuluoma et al published recently a study from the Finnish Care Register of Health. They found that a very large number of drugs intended from neurological or psychiatric conditions were associated with an increased risk of BP. Drugs that particularly elevated the risk for BP included pericazine, melperone, haloperidol, biperiden, and risperidone. However, adjusted odd ratio for antidepressants such as escitalopram, venlafaxine or duloxetine were also significantly associated with BP.

Corticosteroids-Induced Mood Changes

Superpotent topical corticosteroids are currently the gold standard treatment. However, they may be difficult to initiate because of the necessity of help at home (partner or other family members; home nurses). Different national health-care systems may not be always supportive enough in terms of costs. Oral corticosteroid can be the first choice of treatment in
Nevertheless, psychiatric side effects from corticosteroids include mood disorders (mania, mixed states, depression), anxiety, panic disorders, delirium, agitation, insomnia or suicidal behaviour. Symptoms usually occur within the first 1 to 2 weeks after initiation and are dose related. The risk of depression may increase with prolonged or chronic exposure. The first step of treatment in case of psychiatric corticosteroid-induced symptoms is corticosteroid dose reduction or withdrawal. In a spirit of completeness, we wish to remind that both adrenal insufficiency and Cushing syndrome may present as depression.

In conclusion, BP may impact the QoL of the patients with possible direct effect on anxiety or depression. However, the review of the literature shows a dearth in terms of publications on the topic. Depression and anxiety may be related to other comorbidities, such as dementia. BP induced by medications given to treat depression or anxiety should be kept in mind. Corticosteroids may be associated with acute psychiatric symptoms, including depression or anxiety.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Feliciian C, Joly P, Jonkmann MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. *Br J Dermatol.* 2015;172(4):867–877. doi:10.1111/bjd.2015.172.issue-4

2. Schmidt E, Zillikens D. Pemphigoid diseases. *Lancet*. 2013;381(9863):320–332. doi:10.1016/S0140-6736(12)61404-0

3. Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the Pemphigoid diseases. *J Eur Acad Dermatol Venereol.* 2019;33(9):1685–1694. doi:10.1111/jdv.2019.1685

4. Försti AK, Jokelainen J, Timonen M, Tasanen K. Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital. *Br J Dermatol.* 2014;171(5):1223–1226. doi:10.1111/bjd.13189

5. Joly P, Roujeau JC, Benichou J, et al.; Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. *N Engl J Med.* 2002;346(5):321–327. doi:10.1056/NEJMoa011592

6. Parker SR, Dyson S, Brismar S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. *J Am Acad Dermatol.* 2008;59(4):582–588. doi:10.1016/j.jaad.2008.07.022

7. Joly P, Baricault S, Sarsa S, et al. Incidence and mortality of bullous pemphigoid in France. *J Invest Dermatol.* 2012;132(8):1998–2004. doi:10.1038/jid.2012.35

8. Gual A, Mascaro JM Jr, Rojas-Farreras S, Guilabert A, Julià M, Iranzo P. Mortality of bullous pemphigoid in the first year after diagnosis: a retrospective study in a Spanish medical centre. *J Eur Acad Dermatol Venereol.* 2014;28(4):500–506. doi:10.1111/jdv.2014.28.issue-4

9. Lee JH, Kim SC. Mortality of patients with bullous pemphigoid in Korea. *J Am Acad Dermatol.* 2014;71(4):676–683. doi:10.1016/j.jaad.2014.05.006

10. Kalinska-Bienias A, Lukowska-Smorawksa K, Jagielski P, Kowalewski C, Wozniak K. Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. *Arch Dermatol Res.* 2017;309(9):709–719. doi:10.1007/s00427-017-1772-x

11. Terra JB, Potze WJ, Jonkmann MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. *J Eur Acad Dermatol Venereol.* 2014;28(6):712–718. doi:10.1111/jdv.2014.28.issue-6

12. Sebaratnam DF, McMillan JR, Werth VP, Murrell DF. Quality of life in patients with bullous dermatoses. *Clin Dermatol.* 2012;30(1):103–107. doi:10.1016/j.clindermatol.2011.03.016

13. Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases. *J Dermatol.* 2015;42(1):31–36. doi:10.1111/jdv.2014.42.issue-1

14. Kalinska-Bienias A, Jakubowska B, Kowalewski C, Murrell DF, Wozniak K. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease-specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. *Adv Med Sci.* 2017;62(1):92–96. doi:10.1016/j.adms.2016.07.002

15. Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. *An Bras Dermatol.* 2016;91(5):601–603. doi:10.1590/abd1806-4841.20164935

16. DeGrazia TM, Liu Y, Bradley B, et al. LB1101 itch and quality of life impact in atopic dermatitis vs bullous pemphigoid. *J Invest Dermatol.* 2019;139(9):b14. doi:10.1016/j.jid.2019.06.066

17. Sebaratnam DF, Hanna AM, Chee SN, et al. Development of a quality-of-life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. *JAMA Dermatol.* 2013;149(10):1186–1191. doi:10.1001/jamadermatol.2013.4972

18. Försti AK, Jokelainen J, Anskarphi H, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid - a nationwide Finnish Care Register study. *Sci Rep.* 2016;6:37125. doi:10.1038/srep37125

19. Casas-de-la-Asunción E, Ruano-Ruiz J, Rodríguez-Martín AM, Vélez García-Nieto A, Moreno-Giménez JC. Association between bullous pemphigoid and neurologic diseases: a case-control study. *Actas Dermosifiliogr.* 2014;105(9):860–865. doi:10.1016/j.ad.2014.04.013

20. Tarazona MJ, Mota AN, Gripp AC, Unterstell N, Bressan AL. Bullous pemphigoid and neurological disease: statistics from a dermatology service. *An Bras Dermatol.* 2015;90(2):280–282. doi:10.1590/abd1806-4841.20153334

21. Kalinska-Bienias A, Kowalczyk E, Jagielski P, Bienias P, Kowalewski C, Wozniak K. The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: case-control study in a specialized Polish center. *Adv Clin Exp Med.* 2019;28(5):637–642. doi:10.17219/acem/90922

22. Pankakoski A, Sintonen H, Ranki A, Kluger NC. Comorbidities in bullous pemphigoid in a Finnish cohort. *Eur J Dermatol.* 2018;28(2):157–161. doi:10.1684/ ejd.2018.3243

23. Bastuji-Garin S, Joly P, Lemordant P, et al., French Study Group for Bullous Diseases. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. *J Invest Dermatol.* 2011;131(3):637–643. doi:10.1038/jid.2010.301

24. Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. *Br J Dermatol.* 2017;176(1):87–99. doi:10.1111/bjd.2017.176.issue-1

25. Försti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? *Exp Dermatol.* 2017;26(12):1228–1234. doi:10.1111/edx.13401

26. Stavropoulos PG, Soua E, Antoniou C. Drug-induced pemphigoid: a review of the literature. *J Eur Acad Dermatol Venereol.* 2014;28(9):1133–1140. doi:10.1111/jdv.2014.28.issue-9

27. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case-control study. *Arch Dermatol.* 1996;132(3):272–276. doi:10.1001/archderm.1996.03890270044006

Clinical, Cosmetic and Investigational Dermatology downloaded from https://www.dovepress.com/ by 207.241.231.108 on 13-Feb-2020
For personal use only.
28. Wijeratne C, Webster P. Risperidone and bullous pemphigoid. *Am J Psychiatry*. 1996;153(5):735.

29. Rault S, Grosieux-Dauger C, Verraes S, Bernardau K, Durlach A, Bernard P. Bullous pemphigoid induced by fluoxetine. *Br J Dermatol*. 1999;141(4):755–756. doi:10.1046/j.1365-2133.1999.03130.x

30. Varpuluoma O, Jokelainen J, Försti AK, et al. Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: a case-control study. *J Am Acad Dermatol*. 2019;81(1):250–253. doi:10.1016/j.jaad.2019.02.017

31. Kenna HA, Poon AW, de Los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. *Psychiatry Clin Neurosci*. 2011;65(6):549–560. doi:10.1111/j.1440-1819.2011.02260.x

32. Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. *Ann Allergy Asthma Immunol*. 1999;83(6 Pt 1):495–503; quiz 503–4. doi:10.1016/S1081-1206(10)62858-X

33. Vrtanen R, Viikari J. Depression as a first symptom of Addison disease. *Duodecim*. 1998;114(14):1420–1421.

34. Young CA, Williams IR, MacFarlane IA. Unrecognised Cushing’s syndrome and adrenal suppression due to topical clobetasol propionate. *Br J Clin Pract*. 1991;45(1):61–62.

35. Enache D, Winblad B, Aarsland D. Depression in dementia: epidemiology, mechanisms, and treatment. *Curr Opin Psychiatry*. 2011;24(6):461–472. doi:10.1097/YCO.0b013e32834bb9d4

36. Ray S, Agarwal P. Depression and Anxiety in Parkinson Disease. *Clin Geriatr Med*. 2020;36(1):93–104. doi:10.1016/j.cger.2019.09.012